Jan 16, 2019 -
Jan 15, 2019 - ABBV has been mired in a bear market, in large part due to worse-than-expected competition to Humira from biosimilars in the EU.U.S. biosimilars to Humira will enter in 2023, though a competitor is tr
Jan 14, 2019 - Following precipitous revenue losses attributable to its portfolio of HCV medicines, Gilead finds itself in improving financial straits.2019 will see the release of pivotal data from Phase III clinica
Jan 11, 2019 - Agenus received a $1 million grant from the Bill & Melinda Gates Foundation.The company’s lead candidates showed successful phase I/II results.The unique portfolio of antibodies, vaccines, adjuvants,
Jan 09, 2019 - The year closed with a bang, with stock markets tanking, dividend income rising and portfolio restructuring.I outline portfolio composition by sector and portfolio weight for every holding.I have deci
Jan 09, 2019 - Gilead Sciences continues to make a strong push for partnering with or acquiring NASH companies to solidify a stronghold in this space.Results from two selonerstib studies treating patients with NASH,
Jan 09, 2019 - After a dearth of purchase transactions across the industry, M&A has returned in a big way early in 2019 to the biotech space.Both Celgene and Loxo Oncology have been bought out for healthy premiums e
Jan 09, 2019 - It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
Jan 08, 2019 - The big biotech's executives spill the beans on plans for the new year at the J.P. Morgan Healthcare Conference.
Jan 07, 2019 - The current political and economic environment makes Jack Kelly’s examination of the events that ended the Gilded Age both timely and urgent.